3-deazaneplanocin has been researched along with Bone Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adouane, D; Aury-Landas, J; Baugé, C; Boumediene, K; Delépée, R; Girard, N; Lhuissier, E | 1 |
| Clemens, D; Dirksen, U; Hotfilder, M; Klco-Brosius, S; Pettke, A; Potratz, J; Schaefer, C | 1 |
2 other study(ies) available for 3-deazaneplanocin and Bone Neoplasms
| Article | Year |
|---|---|
The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in Chondrosarcomas.
Topics: Adenosine; Animals; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Chondrosarcoma; DNA Damage; Down-Regulation; Enhancer of Zeste Homolog 2 Protein; ErbB Receptors; Histones; Humans; Male; Mice; Mice, Nude; Protein Interaction Maps; RNA Interference; RNA, Small Interfering; S-Adenosylhomocysteine | 2019 |
Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Osteosarcoma; Vorinostat | 2016 |